Dec. 23 at 11:39 AM
$MBOT new year could bring a lot of important updates, I think.
The first set of data from Liberty may pave the way for wider adoption in other hospitals.
I believe this is a smart strategy for a medical device company: focusing on controlled rollout rather than releasing everywhere at once, which could risk machine issues, impact the share price, and potentially harm the company’s reputation.
If this approach works, I wouldn’t be surprised to see major buyout discussions around April at a higher valuation—potentially life-changing money.
